Survival prognostic factors in nonsmall cell lung cancer patients with simultaneous brain metastases and poor performance status at initial presentation.

Both groups with different regimens showed a trend toward longer survival compared with the group receiving standard chemotherapy alone at 13 months (95 % CI, 1.2–24.8); however, no statistically significant difference was observed (p = 0.900, ICI monotherapy vs chemotherapy; p = 0.219, ICI combined therapy vs chemotherapy). 3.3.

also in 53,322 other papers